+$122.3M
Net Activity
Institutions Holding
137
Popularity Rank
#3770
Avg Weight
0.02%
Total Value
$205.8M
137 institutions currently hold OCGN, with 88 net buyers and 37 net sellers this quarter.
Institutional Moves (Q1 2026)
Majority Increased
Based on recent trading activity
Net Selling Institutions
37
Net Buying Institutions
88
Top 5 by Value
+$170.6M
Total Buy Value
$11.7M
Total Sell Value
88
Net Buyers
37
Net Sellers
No Form 144 planned sale filings in the last 90 days
No Schedule 13D/13G filings for this ticker
1
Filings (14d)
On July 13, 2026, Ocugen announced it signed a binding term sheet to license its OCU400 gene therapy for retinitis pigmentosa in the Middle East and North Africa. The press release was filed as Exhibit 99.1 to this 8-K.
View Full Filing (SEC EDGAR)The most-added stocks by 13F institutions this quarter
Institutions Holding
6,150
Total reported value
$2.1T
3245 13F institutions increased their position this quarter
Institutions Holding
5,957
Total reported value
$1.5T
3028 13F institutions increased their position this quarter
Institutions Holding
5,764
Total reported value
$3.0T
2743 13F institutions increased their position this quarter